Bopindolol Malonate | CAS#82857-38-3 (malonate) | 62658-64-4 | Adrenoceptor Antagonist

Bopindolol Malonate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317330

CAS#: 82857-38-3 (malonate)

Description: Bopindolol malonate is a non-selective, potent, long-acting beta adrenoceptor antagonist. It demonstrates inhibition of H2O2-induced lipid peroxdiation. Bopindolol malonate slowly dissociates into the active metabolites 4-(3-tert-butylamino-2-hydroxypropoxy)-2-methyl indole and 4-(3-tert-butylaminopropoxy)-2-carboxyl indole which both demonstrate potent β1-adrenoceptor blocking activity.

Chemical Structure

Bopindolol Malonate

CAS# 82857-38-3 (malonate)

Instruction

Theoretical Analysis

MedKoo Cat#: 317330
Name: Bopindolol Malonate
CAS#: 82857-38-3 (malonate)
Chemical Formula: C26H32N2O7
Exact Mass: 0.00
Molecular Weight: 484.540
Elemental Analysis: C, 64.45; H, 6.66; N, 5.78; O, 23.11

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 180
500mg	USD 500
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 62658-63-3 (free base) 79125-22-7 (furamate) 82857-38-3 (malonate)

Synonym: Bopindolol Malonate; Bopindolol malonate; AC1LCS45; SCHEMBL348872; CTK8F8315; HE393689; LS-120081; D01794; Sandonorm; Bopindolol hydrogen malonate; Wandonorm; Sandonorm (TN)

IUPAC/Chemical Name: [1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate;propanedioic acid

InChi Key: LDOONRJGLKHGJI-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H28N2O3.C3H4O4/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17;4-2(5)1-3(6)7/h5-13,18,24-25H,14-15H2,1-4H3;1H2,(H,4,5)(H,6,7)

SMILES Code: CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3.C(C(=O)O)C(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Certificate of Analysis:

View CoA: current batch, Lot#C9M09C21

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 484.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Belal F, Sharaf El-Din M, Aly F, Hefnawy M, El-Awady M. Fluorometric
determination of bopindolol and celiprolol in pharmaceutical preparations and
biological fluids. J Fluoresc. 2012 Jul;22(4):1141-50. doi:
10.1007/s10895-012-1053-1. Epub 2012 Apr 3. PubMed PMID: 22477063.

2: Meireles J, Sklenárová H, Satínský D, Solich P, Araújo AN, Montenegro MC.
Determination of bopindolol using the flow injection technique coupled with solid
phase extraction. J Pharm Biomed Anal. 2003 Dec 4;33(5):1149-53. PubMed PMID:
14656606.

3: Satínský D, Sklenárová H, Huclová J, Karlícek R. Determination of bopindolol
by sequential injection technique with spectrophotometric detection. Farmaco.
2003 Oct;58(10):1057-62. PubMed PMID: 14505739.

4: Kruk I, Michalska T, Kladna A, Aboul-Enein HY. Spin trapping study of reactive
oxygen species formation during bopindolol peroxidation. Biopolymers. 2002 Oct
15;65(2):89-94. PubMed PMID: 12209459.

5: Urbánek M, Pospísilová M, Polásek M. Determination of bopindolol in
pharmaceuticals by capillary isotachophoresis. J Pharm Biomed Anal. 2002 May
15;28(3-4):509-15. PubMed PMID: 12008130.

6: Nagatomo T, Hosohata Y, Ohnuki T, Nakamura T, Hattori K, Suzuki J, Ishiguro M.
Bopindolol: pharmacological basis and clinical implications. Cardiovasc Drug Rev.
2001 Spring;19(1):9-24. Review. PubMed PMID: 11314603.

7: Nakamura T, Suzuki A, Ohnuki T, Hattori K, Watanabe K, Kurose H, Nagao T,
Nagatomo T. Assessment of affinities of propranolol and bopindolol to membranes
from COS-7 cell transiently transfected with beta-1- and beta-2-adrenoceptors
using a radioligand-binding assay method. Pharmacology. 2000 Jul;61(1):6-10.
PubMed PMID: 10895074.

8: Hattori K, Suzuki J, Hosohata Y, Ohnuki T, Nakamura T, Watanabe K, Muramatsu
I, Nagatomo T. Sustaining effects of bopindolol on inhibitory chronotropic
actions in guinea pig atria. Pharmacology. 1999 Oct;59(4):183-91. PubMed PMID:
10474078.

9: Hattori K, Ishiguro M, Ohnuki T, Nakamura T, Muramatsu I, Nagatomo T.
Identification of binding sites of bopindolol and its two metabolites with
beta1-adrenoceptors by molecular modeling: comparison with beta2 adrenoceptors.
Pharmacology. 1999 Apr;58(4):183-9. PubMed PMID: 10077737.

10: Hosohata Y, Hattori K, Shen Y, Okuyama M, Kaneko H, Ohnuki T, Suzuki J,
Nagatomo T. Bopindolol: a slowly dissociating antagonist from the
beta-adrenoceptors in guinea pig atria. Pharmacology. 1998 Oct;57(4):180-7.
PubMed PMID: 9730775.

11: Aboul-Enein HY, Kruk I, Lichszteld K. Chemiluminescence accompanying
oxidation of bopindolol. Biospectroscopy. 1998;4(4):229-33. PubMed PMID: 9706382.

12: Bagatin J, Sardelić S, Pivac N, Polić S, Ljutic D, Rakic D, Naranca M, Bojić
L, Kovacić Z, Rumboldt Z. Comparison of chlorthalidone, propranolol and
bopindolol in six-month treatment of arterial hypertension. Int J Clin Pharmacol
Res. 1998;18(2):73-8. PubMed PMID: 9675624.

13: Nagatomo T, Ishiguro M, Ohnuki T, Hattori K, Hosohata Y, Takatsu N, Katayama
H, Watanabe K. Studies on relationships between chemical structure and
beta-blocking potency of bopindolol and its two metabolites. Life Sci.
1998;62(17-18):1597-600. PubMed PMID: 9585142.

14: Nagatomo T, Hosohata Y, Ohnuki T, Suzuki J. [Pharmacological characteristics
of the long-acting beta-blocker "bopindolol"]. Nihon Yakurigaku Zasshi. 1997
Jan;109(1):1-12. Review. Japanese. PubMed PMID: 9067994.

15: Hosohata Y, Sasaki K, Maruyama K, Ohnuki T, Hattori K, Suzuki J, Watanabe K,
Nagatomo T. Effects of chronic administration of bopindolol on the binding
characteristics of cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor
subtypes in cardiac muscles of spontaneously hypertensive rats (SHR). Biol Pharm
Bull. 1996 Jul;19(7):932-5. PubMed PMID: 8839963.

16: Widimský J, Lánská V, Hulínský V, Balazovjech I, Havlík V, Havránek P, Kroupa
E, Nikodýmová L, Pátek F, Svítil F, Svihovcová P. [Treatment of hypertension with
a fixed combination of bopindolol and chlorthalidone (Sandoretic)]. Vnitr Lek.
1996 Apr;42(4):223-8. Czech. PubMed PMID: 8693706.

17: Hosohata Y, Sasaki K, Shen Y, Hattori K, Suzuki J, Nagatomo T. Bopindolol is
a slowly dissociating beta 1-adrenoceptor antagonist when compared to other
beta-blockers. Biol Pharm Bull. 1995 Aug;18(8):1066-71. PubMed PMID: 8535397.

18: Hosohata Y, Sasaki K, Suzuki M, Karakisawa Y, Maruyama K, Tsuchihashi H,
Nagatomo T. Alpha-1 and beta-adrenergic receptor blocking potencies of bopindolol
and its two metabolites (18-502 and 20-785) as assessed by radioligand binding
assay methods. Gen Pharmacol. 1995 Jul;26(4):743-7. PubMed PMID: 7635249.

19: Aniya Y, Fong KF, Naito A, Sakanashi M. Antioxidative action of the
beta-adrenoceptor antagonist bopindolol and its metabolite 18-502. Jpn J
Pharmacol. 1995 Jul;68(3):323-9. PubMed PMID: 7474556.

20: Hosohata Y, Suzuki M, Karakisawa Y, Maruyama K, Nagatomo T. The affinity of
bopindolol and its two metabolites for a beta 2-adrenoceptor in the bovine
mesenteric artery. Biol Pharm Bull. 1994 Sep;17(9):1296-8. PubMed PMID: 7841957.

Your view history

Bopindolol Malonate featured